{
    "nct_id": "NCT02673151",
    "official_title": "68-Ga PSMA 11 PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA",
    "inclusion_criteria": "* Histopathological proven prostate adenocarcinoma\n* Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)\n\n  * Post radical prostatectomy (RP) - American Urology Association (AUA) recommendation\n\n    * PSA greater than 0.2 ng/mL measured 6 to 13 weeks after RP\n    * Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA measurements greater than 0.2 ng/mL)\n  * Post-radiation therapy -American Society for Radiation Oncology (ASTRO)-Phoenix consensus definition\n\n    * A rise of PSA measurement of 2 or more ng/mL over the nadir\n* Karnofsky performance status of â‰¥ 50 (or Eastern Cooperative Oncology Group [ECOG] / World Health Organization [WHO] equivalent)\n* Able to provide written consent\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Investigational therapy for prostate cancer.\n* Unable to lie flat, still or tolerate a positron emission tomograpy (PET) scan.\n* Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.",
    "miscellaneous_criteria": ""
}